What is HC Wainwright’s Estimate for NKTR Q1 Earnings?

Nektar Therapeutics (NASDAQ:NKTR) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Nektar Therapeutics in a note issued to investors on Tuesday, December 10th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will post earnings of ($0.17) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.50 price objective on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.79) EPS.

Several other equities analysts have also issued reports on the company. BTIG Research restated a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They issued an “overweight” rating and a $7.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Nektar Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $4.10.

Nektar Therapeutics Stock Up 1.0 %

Shares of Nektar Therapeutics stock opened at $1.02 on Wednesday. Nektar Therapeutics has a 12 month low of $0.46 and a 12 month high of $1.93. The business has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $1.26. The stock has a market cap of $188.15 million, a PE ratio of -1.21 and a beta of 0.57.

Institutional Trading of Nektar Therapeutics

Several hedge funds have recently bought and sold shares of NKTR. Samlyn Capital LLC acquired a new position in shares of Nektar Therapeutics in the second quarter valued at approximately $11,728,000. Eventide Asset Management LLC boosted its position in shares of Nektar Therapeutics by 24.8% during the third quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock worth $12,220,000 after buying an additional 1,870,904 shares during the period. Millennium Management LLC raised its position in Nektar Therapeutics by 56.1% in the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after buying an additional 1,674,924 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in Nektar Therapeutics by 66.0% during the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after purchasing an additional 1,634,046 shares during the last quarter. Finally, State Street Corp grew its position in Nektar Therapeutics by 11.9% in the third quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock valued at $4,349,000 after purchasing an additional 355,759 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.